The total number of records retrieved from this search are 28. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_4509	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 VP/cell	In-vitro result100% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4510	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 4-HP-CP (0.001mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 VP/cell	In-vitro result75% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4511	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 4-HP-CP (0.0025mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 VP/cell	In-vitro result75% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4512	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 4-HP-CP (0.005mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 VP/cell	In-vitro result62% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4513	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP/cell	In-vitro result90% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4514	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 4-HP-CP (0.001mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP/cell	In-vitro result70% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4515	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 4-HP-CP (0.0025mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP/cell	In-vitro result70% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4516	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 4-HP-CP (0.005mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP/cell	In-vitro result70% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4517	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 VP/cell	In-vitro result40% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4518	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 4-HP-CP (0.001mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 VP/cell	In-vitro result35% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4519	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 4-HP-CP (0.0025mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 VP/cell	In-vitro result30% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4520	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 4-HP-CP (0.005mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 VP/cell	In-vitro result35% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4521	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1000 VP/cell	In-vitro result18% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4522	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 4-HP-CP (0.001mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1000 VP/cell	In-vitro result15% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4523	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 4-HP-CP (0.0025mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1000 VP/cell	In-vitro result15% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4524	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with 4-HP-CP (0.005mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1000 VP/cell	In-vitro result15% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4525	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 VP/cell	In-vitro result100% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4526	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Cyclophosphamide (0.0075mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 VP/cell	In-vitro result90% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4527	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Cyclophosphamide (0.05mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1 VP/cell	In-vitro result80% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4528	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP/cell	In-vitro result80% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4529	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Cyclophosphamide (0.0075mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP/cell	In-vitro result70% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4530	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Cyclophosphamide (0.05mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration10 VP/cell	In-vitro result62% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4531	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 VP/cell	In-vitro result40% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4532	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Cyclophosphamide (0.0075mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 VP/cell	In-vitro result40% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4533	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Cyclophosphamide (0.05mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration100 VP/cell	In-vitro result40% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4534	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1000 VP/cell	In-vitro result20% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4535	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Cyclophosphamide (0.0075mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1000 VP/cell	In-vitro result20% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453
IDOV_4536	Virus nameAdenovirus	Virus strainAd5/3-D24-GMCSF	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAd5/3-delta24 has a 24 base-pair deletion in constant region 2 of the E1A gene and armed wirh human GMCSF	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Cyclophosphamide (0.05mg/ml)	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer triple negative cell line	Cell lineMDA-MB-436	Concentration of cell line1000 cells per well	In-vitro toxicityNA	AssayMTS assay	In-vitro virus concentration1000 VP/cell	In-vitro result20% cancer cell survival after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectVirus induced tumor specific T-cell response	Clinical trialNA	PMID27057453